|Assessment Status||Rapid Review Complete|
|Indication||For the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.|
|Rapid review commissioned||24/08/2016|
|Rapid review completed||24/01/2017|
|Rapid review outcome||Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.|
The HSE has approved reimbursement following confidential price negotiations Nov 2017.